The anti-cancer mechanism of IBCs reactivates the cytotoxicity of CD8+ T cells and enhance the anti-tumor immune response in the tumor microenvironment (TME) by blocking the PD-L1/PD-1 signaling pathway [12,13,14,18,19]. The gene discussed is CD8A; the disease is neoplasm.